ECCO 2019 highlights
The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber… read more.
The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber… read more.
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.
As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.
Professor Stefan Schreiber (Germany) discusses the future of therapies in IBD.
Dr Filip Baert (Belgium) discusses the debate at UEGW on treating to target and tight monitoring in IBD.
Dr Johan Burisch (Denmark) reviews data he presented on the cost saving effect of biological therapy in patients with IBD.
Professor Paul Richardson (Boston, USA) presented the results of the OPTIMISMM study which compared the efficacy of pomalidomide, bortezomib and dexamethasone (PVd) with bortezombib and dexamethasone alone (Vd)… read more.
The pathophysiology of MM is characterised by a state of profound immunosuppression through multiple mechanisms which provides a strong rationale for immunotherapeutic approaches including antibodies, immunomodulators, vaccines and… read more.
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.
Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.
Advertisment